JPRN-UMIN000032092
Completed
未知
Continuous blood glucose measurement in neonates - Continuous blood glucose measurement in neonates
Maternal-Fetal and Neonatal Care Center, Hamamatsu University Hospital0 sites20 target enrollmentMay 11, 2018
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Maternal-Fetal and Neonatal Care Center, Hamamatsu University Hospital
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Neonate with inborn diagnosis of congenital anomaly Neonate who entered the neonatal intensive care unit due to premature birth or complications
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Patient Reported Outcome Measurement in Pancreatic SurgeryC25K86Malignant neoplasm of pancreasOther diseases of pancreasDRKS00020475niversitätsklinikum Schleswig-Holstein Campus Lübeck203
Completed
Not Applicable
A randomised, placebo-controlled, titration-to-effect, crossover study of study drug 038 in patients with chronic low back paiChronic low back painMusculoskeletal DiseasesDorsalgiaISRCTN35931095Purdue Pharma Canada100
Completed
Not Applicable
Patient Journey in Phosphate DiabetesE83.30DRKS00015510Klinische StudieneinheitOrthopädische Klinik, Universität Würzburg73
Active, not recruiting
Phase 1
Pirfenidone in heart failure with preserved ejection fractioHeart failure with preserved ejection fraction (HFpEF)MedDRA version: 19.0Level: LLTClassification code 10069211Term: Diastolic heart failureSystem Organ Class: 100000004849MedDRA version: 19.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2016-002647-42-GBniversity Hospital of South Manchester
Active, not recruiting
Not Applicable
A double-blind, randomised, placebo controlled, phase I/IIa dose escalation study to investigate the safety and the effect of different doses of Oralgen House Dust Mite in patients with house dust mite induced allergic rhinoconjunctivitisEUCTR2008-003879-49-GBArtu Biologicals Europe B.V.